ROCK1 inhibition primes anti-tumor immunity in EGFR-mutant NSCLC by triggering PD-L1 degradation mediated by SMURF2.

Mol Cancer · 2026 · PMC13169767 · PMID 41928228

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Comprehensive profiling of other immune populations revealed no significant changes following ROCK1 inhibition, although a decreasing trend was observed in regulatory T cells and M2-like macrophages (Supplementary Fig. 3).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.